The subgroup analyses in this study indicated that KCNQ1OT1 methylation has the potential to help in assessing the risk of luminal A and HER-2-overexpressing subtypes of BC, while PHLDA2 methylation could also be a novel marker to assess the risk of luminal B subtype BC. This evidence concerns the gene ERBB2 and breast cancer.